stockrowDr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
Follow RDY
Alert me
Dr. Reddy's Laboratories Ltd (RDY) EBITDA
Dr. Reddy's Laboratories Ltd's EBITDA for fiscal 2026 was $759.0M, down 27.2% from $1.0B in fiscal 2025. Over the twelve months to 30 September 2026 it was $526.8M. Over the past ten years it has ranged from $363.0M (fiscal 2018) to $1.0B (fiscal 2025); the current reading is higher than 75% of that period. Dr. Reddy's Laboratories Ltd ranks 11th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | $759.0M | (27.16%) |
| FY2025 | $1.0B | 5.25% |
| FY2024 | $990.0M | 16.61% |
| FY2023 | $849.0M | 55.78% |
| FY2022 | $545.0M | (12.66%) |
| FY2021 | $624.0M | 4.00% |
| FY2020 | $600.0M | 25.52% |
| FY2019 | $478.0M | 31.68% |
| FY2018 | $363.0M | (4.97%) |
| FY2017 | $382.0M | (36.54%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $187.2M | 90.99% |
| Jun 2026 | $98.0M | 274.98% |
| Mar 2026 | $26.1M | (87.87%) |
| Dec 2025 | $215.5M | (15.96%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| VTRS Viatris Inc. compare | $2.7B |
| NBIX Neurocrine Biosciences, Inc. compare | $976.5M |
| ELAN Elanco Animal Health Incorporated compare | $774.0M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $664.9M |
| RDY Dr. Reddy's Laboratories Ltd | $526.8M |
| LNTH Lantheus Holdings, Inc. compare | $386.4M |
| ALKS Alkermes plc compare | $217.3M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $132.4M |
| HIMS Hims & Hers Health, Inc. compare | −$62.2M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on RDY
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement